Key facts
- This page summarizes David Arkowitz's Form 4 filing for Flexion Therapeutics Inc.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 May 2021, 17:06.
David Arkowitz - 10 May 2021 Form 4 Insider Report for Flexion Therapeutics Inc
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 10 May 2021
- Net transaction value
- -$16,116
- SEC form
- 4
- Accepted by SEC
- 12 May 2021, 17:06:20 UTC
- Prior SEC filing
- 09 Mar 2023
- Next SEC filing
- 01 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark S. Levine, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Arkowitz filed Form 4 for Flexion Therapeutics Inc on 12 May 2021.
Change
- Previous filing in this sequence was filed on 09 Mar 2023.
- Current net transaction value: -$16,116.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FLXN
transaction
Common Stock
Sale
- Transaction value
- $16,116
- Shares
- -2,229
- Change %
- -1%
- Price
- $7.23
- Shares after
- 220,719
- Date
- 10 May 2021
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Sale of shares to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on June 1, 2018.
Footnote F2
The weighted average sale price for the transaction reported was $7.23. The shares were sold at a range of prices between $7.14 and $7.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.